Conference Track

First-Line Therapy and Switch Strategies

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Lopinavir Trough Levels Lower in Pregnant vs Nonpregnant HIV-Infected Women
DAUFIN Study: Once-Daily Regimen of Lamivudine, Tenofovir, and Nevirapine Associated With High Rate of Early Virologic Failure
Didanosine, Lamivudine, and Efavirenz Appear as Effective and Better Tolerated Than Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Individuals
Efavirenz Associated With Better Outcomes, Better Adherence in HIV-Infected Veteran Population
Short-term Virologic Failure May Not Be a Consistent Marker for Clinical Outcomes With Combination ART
Tshepo Study Suggests NNRTI With Either Zidovudine/Lamivudine or Stavudine + Lamivudine Highly Effective in Treating HIV-1C Infection in Botswana
Early Treatment of Primary HIV-1 Infection Associated With Lower Viral Set Point
Use of HAART in Primary HIV Infection Does Not Lower Viral Set Point After Discontinuation vs Untreated Primary Infection
HIV-1 RNA Predicts Clinical Disease Progression but Not CD4+ Cell Count Decline
Use of Atazanavir in Pregnancy: No Association With Early Infant Morbidity in Case Series
Time to Virologic Failure in Treatment-Naive Patients Receiving Lopinavir/Ritonavir-Based HAART Does Not Differ With Once-Daily vs Twice-Daily Dosing or With DOT
Suboptimal Care of HIV Infection Reduces Life Expectancy, Especially for Women and Racial Minorities

Expert Analysis

Clinical Update on First-Line Antiretroviral Therapy

Faculty:
David A. Cooper, MD, DSc Joel E. Gallant, MD, MPH Kimberly Y. Smith, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of studies investigating the use of boosted PIs in the treatment of pregnant HIV-infected women
Discuss whether the rate of initial viral decay is associated with long-term virologic outcomes of therapy
Summarize the results of recent studies utilizing FDA-approved and investigational antiretrovirals as first-line regimens in HIV-infected patients
Specify considerations that may influence the choice of first-line antiretroviral regimens in resource-limited settings
Describe recent data on the predictive value of viral load in determining CD4+ cell count decline and disease progression

CME CREDIT INFORMATION

Release Date: 04/26/07

Expiration Date: 04/25/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.6 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.